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Low concentrations at the tumour site and dose-limiting systemic
toxicity are common causes for failure of solid tumour treatment
with anti-tumour agents. As cytotoxic drugs typically exhibit a
steep dose–response curve, increasing local concentration should
favour tumour response. In isolated limb perfusions (ILP) local
drug concentrations are increased while systemic exposure to the
drugs is minimal. In ILP melphalan is used most commonly, but
other agents (e.g. doxorubicin and cisplatin) are also applied with
varying success in perfusion of limb or organ (e.g. lung) (Tonak et
al, 1979; Klaase et al, 1989; Rossi et al, 1992; Weksler et al, 1994;
Abolhoda et al, 1997). Tumour necrosis factor alpha (TNF-a), a
cytokine with known anti-tumour activity, cannot be used system-
ically in dosages high enough to obtain a tumour response (Asher
et al, 1987; Fajardo et al, 1992). However, in ILP with TNF-a,
tumours are exposed to concentrations of up to 50 times higher
than those reached after systemic administration of the maximum
tolerated dose (MTD), without major side-effects (Benckhuijsen 
et al, 1988). Previously it was demonstrated that the addition of
TNF-a to melphalan in ILP could improve response rates in
patients with multiple melanoma in transit metastases or irre-
sectable soft tissue extremity sarcomas (Lienard et al, 1992, 1994;
Eggermont et al, 1993, 1996a, 1996b; Lejeune et al, 1993). In both
patient groups very high response rates of above 85% have been
reported, with a limb salvage rate of more than 85%. In Europe,
TNF-a was recently approved and registered for clinical use in
patients for the treatment of locally advanced extremity soft tissue
sarcomas by ILP with TNF-a and melphalan. Comparable results
have been reported by us for ILP with the combination of TNF-a
and melphalan in soft tissue sarcoma and osteosarcoma-bearing
rats (Manusama et al, 1996a, 1996b; de Wilt et al, 1999). ILP with
TNF-a alone or melphalan alone at concentrations used in the
clinical setting had negligible anti-tumour effects, whereas the
combination showed strong synergistic anti-tumour efficacy.
TNF-a may potentiate the effects of chemotherapy in ILP in
various ways. TNF-a has a broad spectrum of activities, which
range from enhancement of proliferation to direct cytotoxicity on
tumour cells, activation of inflammation and effects on endothe-
lium (Watanabe et al, 1988; Fajardo et al, 1992). The tumour-asso-
ciated vasculature (TAV) responds to TNF-a with rounding of the
endothelial cells resulting in increased gaps, allowing easy
passage of soluble materials and even cells (Smyth et al, 1988;
Folli et al, 1993; Renard et al, 1995). Moreover, intravenous
injection of TNF-a in human melanoma xenograft-bearing mice
resulted in significant reduction of the interstitial fluid pressure
(IFP) of the tumours (Kristensen et al, 1996). This phenomenon
could increase localization of cytotoxic drugs in the tumour inter-
stitium and explain improved tumour response. Secondly, clinical
and experimental results demonstrating massive destruction of the
endothelial cells, which has also been shown in vitro and on
angiograms in patients after ILP, suggest that the TAV is the
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endothelial lining might be responsible for the anti-tumour
response (Sato et al, 1986; Watanabe et al, 1988; Olieman et al,
1997). This process was accompanied by inflammatory responses
and seemed to be dependent on infiltrating leucocytes (Manusama
et al, 1998). Coagulative and haemorrhagic necrosis and destruc-
tion of the endothelial lining was also seen when TNF-a was used
as a single agent in ILP, without significant effect, however, on
tumour growth in rats. This indicates that the direct TNF-a effect
is most likely playing a minor role in the anti-tumour capacity
(Manusama et al, 1996a; Nooijen et al, 1996a).
Although in the majority of the perfusions, especially for the
treatment of melanoma, melphalan is used, other agents might also
be successful. Anthracyclines are among the most active agents
against solid tumours and doxorubicin is the most widely used
agent of this class (Budd, 1995; Bielack et al, 1996). Moreover,
doxorubicin is the agent of choice for the treatment of sarcoma,
and has shown good anti-tumour activity in clinical and experi-
mental perfusion settings for the treatment of lung metastases
(Weksler et al, 1994; Abolhoda et al, 1997), and could therefore be
a suitable cytotoxic agent for ILP in sarcoma-bearing patients.
In this study we undertook ILP with doxorubicin and TNF-a in
soft tissue sarcoma- and osteosarcoma-bearing rats to examine the
effect of TNF-a on the anti-tumour activity of doxorubicin.
Secondly, an attempt was made to unravel possible mechanisms by
which TNF-a potentiates the anti-tumour activity of doxorubicin.
MATERIALS AND METHODS
Chemicals
Human recombinant TNF-a (specific activity 5 ´ 107 IU mg–1)
was kindly provided by Dr G Adolf (Bender Wien GmbH, Wien,
Austria) and stored at a concentration of 2 mg ml–1 at –80°C 
or under liquid nitrogen. Endotoxin levels (LAL) were below
0.624 EU mg–1. Doxorubicin (Adriablastina®) was purchased
from Farmitalia Carlo Erba (Brussels, Belgium).
Animals and tumour model
Male inbred BN rats were used for the soft tissue sarcoma 
model (BN175) and WAG/RIJ rats for the osteosarcoma model
(ROS-1). Rats were obtained from Harlan-CPB (Austerlitz, The
Netherlands) and weighed 250–300 g. Small fragments (3 mm) 
of the syngeneic BN175 or ROS-1 sarcoma were implanted 
subcutaneously in the right hindleg as previously described
(Manusama et al, 1996a; 1996b). Tumour growth was recorded by
calliper measurements and tumour volume calculated using the
formula 0.4(A2 ´ B) (where B represents the largest diameter and
A the diameter perpendicular to B). All animal studies were 
done in accordance with protocols approved by the Animal 
Care Committee of the Erasmus University Rotterdam, The
Netherlands.
The classification of tumour response was: progressive disease
(PD), increase of tumour volume (> 25%) within 5 days; no
change (NC), tumour volume equal to volume during perfusion in
a range of –25% and + 25%; partial remission (PR), decrease of
tumour volume between –25% and –90%; complete remission
(CR), tumour volume less than 10% of initial volume.
ILP protocol
Rats were perfused according to the ILP technique originally
described by Benckhuijsen et al (1982a) and adapted for the rat by
Manusama et al (Manusama et al, 1996a). Briefly, the femoral
artery and vein of anaesthetized rats were cannulated with silastic
tubing. Collaterals were occluded by a groin tourniquet and perfu-
sion started when the tourniquet was tightened. The extracorporeal
circuit included an oxygenation reservoir and a roller pump
(Watson Marlow, Falmouth, UK). The perfusion was performed
with 5 ml Haemaccel (Behring Pharma, Amsterdam, The
Netherlands) and TNF-a (50 mg) and/or doxorubicin (400 mg
BN175 and 200 mg ROS-1) were added as boluses to the oxygena-
tion reservoir. Control rats (sham) were perfused with Haemaccel
alone. The concentration of TNF-a was adapted from previous
animal studies and doxorubicin concentrations chosen had no 
local toxicity and induced maximally stable disease after single
perfusion (Manusama et al, 1996a). ILP with lower doxorubicin
dosages or TNF dosages below 10 mg resulted in comparable or
diminished tumour response (de Wilt et al, 1999). Perfusion was
maintained for 30 min at a flow rate of 2.4 ml min–1. During the
perfusion the hindleg of the rat was kept at a temperature of
38–39°C with a warm water mattress. A washout with 2 ml
oxygenated Haemaccel was performed at the end of the perfusion.
Perfusion was performed at a tumour diameter of 12–15 mm,
which is around 7 or 10 days after implantation for BN-175 and
ROS-1 respectively.
In vitro assessment of anti-tumour activity
BN175 soft tissue sarcoma cells or ROS-1 osteosarcoma cells
were added in 100 ml aliquots to 96-well plates at a final concen-
tration of 104 cells per well and allowed to grow as a monolayer in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS). Doxorubicin and/or TNF-a were
diluted in DMEM supplemented with 10% FCS, added to the wells
and allowed to incubate for 3 days. The range of final drugs in the
wells was 0.0005–100 mg ml–1 for doxorubicin and 0–10 mg ml–1
for TNF-a. A total of 5–6 separate assays were performed in tripli-
cate and the percentage of growth inhibition calculated according to
the formula: percentage of tumour cell growth = (test well/control
well) ´ 100%. Percentage of tumour cell cytotoxicity was measured
using the sulphorhodamine B assay (Keepers et al, 1991).
In vitro assessment of doxorubicin uptake in tumour
cells
To determine if the observed anti-tumour response after ILP and
cytotoxicity in vitro correlated with cellular uptake of doxo-
rubicin, cells were exposed to doxorubicin with and without TNF-
a and intracellular doxorubicin levels determined by flow
cytometry as previously described (Luk and Tannock, 1989).
Briefly, BN175 soft tissue sarcoma cells or ROS-1 osteosarcoma
cells were added in 500-ml aliquots to 24-well plates at a final
concentration of 5 ´ 104 cells per well and allowed to grow as a
monolayer in DMEM supplemented with 10% FCS. Doxorubicin
and TNF-a were diluted in DMEM supplemented with 10% FCS
and added to the wells, after which cells were incubated for 0, 10,
30, 60 and 120 min. The final drug concentration in the wells was
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Thereafter monolayers were treated with trypsin–EDTA for 2 min
and the cell suspensions were washed two times in complete
medium and resuspended in phosphate-buffered saline (PBS).
Cellular uptake was measured on a Becton Dickinson FACScan
using Cell Quest software on Apple Macintosh computer.
Excitation was set at 488 nm and emission at 530 nm.
Fluorescence was corrected for cell size using the forward scatter
(FSC) with the formula corrected fluorescence (FLcor) = fluores-
cence at 530 nm (FL530)/FSC-FL530c/FSCc (FL530c and FSCc are
fluorescence and forward scatter with no drug added to the cells).
Assessment of doxorubicin accumulation in solid
tumour and concentration in perfusate during ILP
To determine the influence of TNF-a on doxorubicin accumula-
tion in tumours during ILP, tumours (and muscle) were surgically
removed after ILP and total doxorubicin content determined as
previously described (Mayer et al, 1989). As the ILP included a
thorough washout there was no intravascular doxorubicin present.
Briefly, after incubation in acidified isopropanol (0.075 N hydro-
chloric acid in 90% isopropanol) for 24 h at 4°C, the tumours were
homogenized (PRO200 homogenizer with 10-mm generator, Pro
Scientific, CT, USA), centrifuged for 30 min at 2500 rpm and
supernatants harvested. Samples were measured in a Hitachi
F4500 fluorescence spectrometer (excitation 472 nm and emission
590 nm) and compared with a standard curve prepared with known
concentrations of doxorubicin diluted in acidified isopropanol.
Measurements were repeated after addition of an internal doxo-
rubicin standard. Detection limit for doxorubicin in tissue was 
0.1 mg g–1 tissue.
For perfusate measurements samples were drawn from the
perfusion vial at 0.5, 5, 15 and 30 min after ILP was started.
Samples were centrifuged for 30 min at 2500 rpm and supernatant
measured for doxorubicin content as described above. Cell pellets
were incubated in acidified isopropanol and doxorubicin content
determined as described above.
Statistical analysis
The in vivo and in vitro results were evaluated for statistical signi-
ficance using the Mann–Whitney U-test with SPSS for windows.
In vitro data were analysed by curve fitting using GraphPad Prism.
P-values below 0.05 were considered statistically significant.
RESULTS
In vivo tumour response to doxorubicin and TNF-a
To evaluate the anti-tumour activity of doxorubicin when
combined with TNF-a in an ILP setting, soft tissue sarcoma and
osteosarcoma-bearing rats were perfused with the agents
combined or alone. Figure 1 shows the tumour responses of soft
tissue sarcoma (BN175) in rats after ILP. Perfusion with buffer or
TNF-a alone resulted in progressive disease in all animals.
Although ILP with doxorubicin (400 mg) alone resulted in a slight
inhibition of the BN175 tumour growth when compared with the
sham control, none of the rats showed a tumour response (Table 1).
ILP with 400 mg doxorubicin combined with 50 mg TNF-a
resulted in increased anti-tumour activity with a response rate of
54% (PR and CR combined; P < 0.01 compared with doxorubicin
alone).
In osteosarcoma (ROS1)-bearing rats ILP with buffer or
doxorubicin (200 mg) alone had no significant effect on tumour
growth (Figure 2). ILP with TNF-a alone resulted in significant
inhibition of tumour growth as compared with the sham perfusion
Effect of TNF-a on isolated perfusion with doxorubicin 975
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Figure 1 Growth curves of subcutaneous implanted soft tissue sarcoma
BN175 after isolated limb perfusion with medium alone (n), 50 mg TNF-a (s),
400 mg doxorubicin (t), or combination of TNF-a and doxorubicin (l). Mean
tumour volumes are shown ± s.e.m. Number of rats per group is shown in
Table 1
Table 1 Tumour response of BN-175 after ILP with doxorubicin and TNF-a
during 5 days after treatment
Responsea Sham TNF-ab Doxorubicin Doxorubicin + TNF-a
n = 12 n = 10 n = 10 n = 13
PD 12 10 6 2
NC 4 4
PR 6
CR 1
Response rate (PR and CR) 54%
aResponses were scored as described in Materials and Methods. bTNF-a
and doxorubicin, 50 and 400 mg respectively, were added to the perfusate 
(5 ml) as boluses. cPD: progressive disease, NC: no change, PR: partial
remission, CR: complete remission.
Table 2 Tumour response of ROS-1 after ILP with doxorubicin and TNF-a
during 5 days after treatment
Responsea Sham TNF-ab Doxorubicin Doxorubicin + TNF-a
n = 8 n = 9 n = 8 n = 10
PD 8 3 2
NC 3 6
PR 1 6
CR 2 4
Response rate (PR and CR) 33% 100%
aClassification of response rates is described in Materials and Methods.
bTNF-a and doxorubicin, 50 and 200 mg respectively, were added to the
perfusate (5 ml) as boluses. PD: progressive disease, NC: no change, PR:
partial remission, CR: complete remission.and a response rate of 33% was observed (Table 2). ILP with 
200 mg doxorubicin combined with 50 mg TNF-a further
increased the anti-tumour response with a response rate of 100%
(PR and CR combined; P < 0.05 compared with TNF-a alone).
In vitro assessment of anti-tumour activity of
doxorubicin and TNF-a
The in vivo experiments clearly demonstrate pronounced improve-
ment of tumour response when doxorubicin was used in combina-
tion with TNF-a. In vitro experiments were performed to further
study the nature of this interaction. Exposure of soft tissue
sarcoma BN175 or osteosarcoma ROS-1 tumour cells to doxo-
rubicin resulted in a response curve with an IC50 of 0.1 and 
2.0 mg ml–1 respectively (Figure 3). No significant cellular toxicity
could be observed when BN175 cells were exposed to TNF-a
alone; however, a dose-dependent growth reduction was observed
when ROS-1 cells were exposed to TNF-a with a maximum
reduction of 38% at 10 mg ml–1. Addition of TNF-a to doxorubicin
did not significantly alter the IC50 of doxorubicin in the BN-175
cell cultures, indicating that addition of TNF-a in vitro did not
influence the sensitivity of the cells to doxorubicin significantly.
On ROS-1 cells only an additive effect of TNF-a and doxorubicin
was observed. The curve only shifted downwards and not to a
lower doxorubicin concentration, which indicates that the drugs do
not influence each other but have separate effects.
In vitro uptake of doxorubicin in tumour cells
Figure 4 shows that increased intracellular concentrations of
doxorubicin are observed in both cell types when cells were incu-
bated with increasing concentrations of doxorubicin. A tenfold
higher doxorubicin concentration in culture supernatant (ranging
from 1.0 to 10 mg ml–1) resulted in 4.5-fold and 3.9-fold
augmented cellular uptake for BN175 and ROS-1 respectively 
(P < 0.01 and P < 0.05). Addition, however, of TNF-a to the
culture medium did not influence intracellular doxorubicin content
significantly for all the TNF-a concentrations tested, or even a
slight but not significant reduction in uptake was noticed with
increasing concentrations of TNF-a (Figure 5).
Doxorubicin accumulation in solid tumour after ILP
Possibly the observed beneficial effect of TNF-a in vivo could be
explained by an increased extravasation of doxorubicin into the
tumour interstitium, resulting in a higher local concentration and
accordingly in an improved anti-tumour activity. Therefore,
concentrations of doxorubicin in tumour and surrounded tissue
after ILP were determined. Figure 6 shows that measurable
amounts of doxorubicin localized both in BN175 and ROS-1
tumours after ILP, which correlates with an observed decline of the
drug concentration in the perfusate (data not shown). Moreover,
addition of TNF-a to the perfusate resulted in significantly
enhanced accumulation of doxorubicin in both these tumours, 3.1-
fold in the BN175 and 1.8-fold in the ROS-1 sarcoma, when
compared with ILP with doxorubicin alone. Addition of TNF had
no significant effect on doxorubicin accumulation in muscle of the
leg (P > 0.4). Strikingly, a significant discrepancy in drug levels
was observed between BN175 and ROS-1 tumours.
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Figure 2 Growth curves of subcutaneous implanted osteosarcoma ROS-1
after isolated limb perfusion with medium alone (n), 50 mg TNF-a (s), 
200 mg doxorubicin (t), or combination of TNF-a and doxorubicin (l). Mean
tumour volumes are shown ± s.e.m. Number of rats per group is shown in
Table 2
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Figure 3 In vitro growth of (A) BN175 and (B) ROS-1 tumour cells as
function of the doxorubicin concentration in combination with 0 mg (l), 0.1 mg
(s), 1.0 mg (t) or 10 mg TNF-a per ml (n). The mean of 5–6 individual
experiments performed in triple is shown ± s.e.m.Effect of TNF-a on isolated perfusion with doxorubicin 977
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Figure 4 Uptake of doxorubicin by (A and C) BN175 tumour cells, or (B and D) ROS-1 tumour cells in vitro as determined by flowcytometry after exposure of
the cells to 0, 0.1, 1.0 or 10 mg ml–1 doxorubicin for 2 h (A and B) or for various durations of time at a fixed doxorubicin concentration of 10 mg ml–1 (C and D).
The graphs are good representatives of the experiments performed
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Figure 5 Uptake of doxorubicin in (A) BN175 or (B) ROS-1 tumour cells in vitro at respectively 120 and 60 min of exposure to the agent in the presence of 0,
0.1, 1.0 or 10 mg TNF-a per ml. The mean of 5 experiments is shown ± s.d.DISCUSSION
In the present study we demonstrate that ILP in sarcoma-bearing
rats with doxorubicin in combination with TNF-a results in high
response rates in two different tumour models. These findings are
in close agreement with our previous work using melphalan
(Manusama et al, 1996a, 1996b). Secondly, it is demonstrated for
the first time that TNF-a enhances intratumoural accumulation of
doxorubicin, which is an attractive explanation for the augmented
tumour response in TNF-a-based ILP. We speculate that TNF-a
increases interstitial drug levels in the tumour as intravascular
doxorubicin is washed out at the end of the ILP procedure and
intracellular uptake of doxorubicin is not affected by TNF-a as
was shown in vitro.
Doxorubicin has been shown to be the most effective drug in
treatment of sarcomas and therefore put forward as the drug of
choice in the treatment of these malignancies (Budd, 1995;
Bielack et al, 1996). Here we demonstrate that perfusion with
doxorubicin alone is not, or only partially, effective, which is also
observed when melphalan is used as a single agent in the perfusion
setting.
A striking observation is the augmentation of the doxorubicin-
induced anti-tumour response by TNF-a in vivo, which has also
been shown for melphalan and TNF-a in these tumour models
(Manusama et al, 1996a, 1996b). Strong tumour responses were
observed in both models after ILP with the combination therapy,
which cannot be explained by just adding up the responses after
ILP with the single agents. An important observation is that
chemotherapy by itself is not, or partially, effective as shown here
and by others (Klaase et al, 1989). Secondly, it was previously
shown in our rat tumour model as well as in the clinic that ILP
with TNF-a alone had no effect on tumour growth although
massive haemorrhagic necrosis and pathology was observed
(Posner et al, 1994; Manusama et al, 1996a; Nooijen et al, 1996).
These observations indicate that other mechanisms have to be
identified to explain the interaction between TNF-a and
chemotherapy.
Several specific activities of TNF-a could potentiate the anti-
tumour activity of chemotherapy. It has been postulated that the
increased tumour response observed after ILP with melphalan and
TNF-a is due to destruction of the TAV, resulting in haemorrhagic
necrosis, platelet aggregation and erythrostasis (Watanabe et al,
1988; Nooijen et al, 1996). Moreover, it has been shown recently
that perfusion with melphalan in combination with TNF-a and
interferon gamma (IFN-g) resulted in apoptosis of endothelial cells
of the TAV (Ruegg et al, 1998). Inflammatory events such as gran-
ulocyte infiltration were also suggested to play a role (Nooijen et
al, 1996; Manusama et al, 1998). These findings led to the specu-
lation that destruction of the TAV is the mechanism by which
TNF-a potentiates cytotoxic agents. Watanabe et al demonstrated
toxic effects of TNF-a on newly formed tumour vasculature in
mice, resulting in haemorrhage, congestion and blood circulation
blockage (Watanabe et al, 1988). Congestion and blockage of the
blood circulation could result in impaired drainage of the tumour
leading to the observed augmented tumour concentrations. Others
suggested that TNF-a-induced thrombus formation played an
important role (Shimomura et al, 1988). However, these effects are
also observed after perfusion with TNF-a alone (Nooijen et al,
1996).
Recent studies show that perfusion of melanoma-bearing
patients with melphalan in combination with TNF-a and IFN-g
results in detachment and apoptosis of endothelial cells of the
tumour (Ruegg et al, 1998). Moreover, the in vitro experiments
demonstrated an important role for TNF-a and IFN-g mediated
down-modulation of the avb3 function, which is speculated to play
a prominent role in the in vivo observations. These findings would
argue in favour for a TNF-a-mediated destruction of the vascula-
ture. The in vitro observations also demonstrated the necessity of
IFN-g for the induction of endothelial apoptosis. On the other hand
it has been shown in our model, as well as in various clinical trails,
that tumour responses are only slightly improved by the addition
of IFN-g (Eggermont et al, 1996b; Lienard et al, 1992b). This
would argue against an important role for TNF-a-mediated
destruction of the TAV in the tumour response; it also indicates
that endogenous produced IFN-g is of major importance.
A consistent finding in our two models is the augmented accu-
mulation of doxorubicin in tumour tissue when TNF-a is added to
the perfusate. In both models this increase could very well explain
the improved efficacy. On the other hand, TNF-a may increase the
uptake of doxorubicin by the tumour cells. However, intracellular
concentration of doxorubicin in vitro was not enhanced when
TNF-a was added in vitro. Moreover, TNF-a did not seem to
affect the in vitro cytotoxic activity of doxorubicin significantly. In
contradiction to these findings, synergy between TNF-a and
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Figure 6 Accumulation of doxorubicin in (A) soft tissue sarcoma BN175 or
(B) osteosarcoma ROS-1 in vivo during isolated perfusion. Rats were
perfused with doxorubicin (400 mg BN175 and 200 mg ROS-1) with 50 mg
TNF-a or without TNF-a, after which tumours and muscle were excised and
total doxorubicin content determined as described in Materials and Methods.
The mean of 6 rats is shown ± s.d.doxorubicin in vitro has been shown in previous studies depending
on sensitivity of the cells to TNF-a, presence of multidrug resis-
tance or order of exposure (Alexander et al, 1987; Bonavida et al,
1990; Soranzo et al, 1990; Fruehauf et al, 1991). This effect has
also been shown without an increased intracellular accumulation
of doxorubicin (Safrit et al, 1993). Others demonstrated that expo-
sure of tumour cells to TNF-a resulted in a reduced sensitivity of
these cells to doxorubicin (Prewitt et al, 1994). It is suggested that
arrest of the cells in the G1/0 phase by TNF-a turns them insensi-
tive to doxorubicin, which is a cell cycle-dependent cytotoxic
agent. In our study we did not observe such phenomenon when the
tumour cells were exposed to doxorubicin and TNF-a. These
observations suggest that in vivo TNF-a has an indirect effect on
the anti-tumour activity of doxorubicin. Therefore, we postulate
that TNF-a augments the accumulation of doxorubicin in the
tumour by increasing the leakiness of the TAV, and by doing so
increases the local drug level. Previously an increased leakiness of
the TAV as well as a reduction of the IFP in tumour has been
shown by others after systemic administration of TNF-a (Smyth et
al, 1988; Folli et al, 1993; Renard et al, 1995; Kristensen et al,
1996). In patients and in other experimental models, accumulation
of doxorubicin in tumour was found to fluctuate between 1.0 and
7.0 mg g–1 tissue after intravenous treatment, but considerably
higher when locally infused (around 20 mg g–1 tumour), which is
comparable with our findings when ILP is performed with doxoru-
bicin alone (Lee et al, 1980; Ridge et al, 1988; Murdter et al,
1997). Moreover, increased drug accumulation in tumour has
previously been shown after systemic treatment with TNF-a when
a liposomal doxorubicin preparation was injected (Suzuki et al,
1990). It must be kept in mind that accumulation of drug in tumour
not only depends on treatment procedure but also on the type of
tumour. Preliminary results from a clinical phase I–II trial with
doxorubicin and TNF-a in hyperthermic ILP demonstrated
comparable favourable outcome as is obtained with melphalan and
TNF-a (Di Filippo et al, 1998).
From our study we propose that the observed augmentation of
the anti-tumour activity of doxorubicin by TNF-a is mainly due to
an increased accumulation of doxorubicin in the tumour during
ILP as is shown in both models. A direct effect of TNF-a on the
sensitivity of the tumour cells to doxorubicin was ruled out by in
vitro examinations.
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